C1 Esterase Inhibitor (Ruconest)

Ruconest is covered for treatment of acute hereditary angioedema (HAE) attacks in adolescents and adults ≥13 with HAE confirmed by low C4 and abnormal C1‑INH antigenic or functional levels, and is excluded for HAE‑related laryngeal attacks, patients with life‑threatening hypersensitivity to C1‑INH products or rabbit allergy, and use in combination with other acute HAE agents. Coverage requires documentation of diagnosis and C4/C1‑INH lab results, patient age ≥13, confirmation the request is for an acute attack, attestation of no history of laryngeal attacks or anaphylaxis to C1‑INH products and no rabbit allergy, and monitoring for hypersensitivity and thromboembolic events is recommended.

"Treatment of acute attacks of hereditary angioedema (HAE) in adult and adolescent patients."

Sign up to see full coverage criteria, indications, and limitations.